Accentia shares plunge on Phase III failure

Accentia Biopharmaceuticals disappointed its investors with a surprise announcement late Monday that a Phase III trial of SinuNase for chronic sinusitis had failed to hit its primary endpoint. The company's stock plunged 73 percent on the news, dropping to 81 cents a share. Officials for the company had expressed a significant amount of confidence in the therapy. The late-stage trial tested SinuNase in treating fluid buildup in sinuses.

But Accentia isn't abandoning the drug. "The company continues to believe that SinuNase is a viable product candidate for the treatment of chronic sinusitis, and a full data analysis of both the primary and secondary endpoints will be conducted in order to determine the next steps necessary in order to advance the product," Accentia said in a statement.

- see this release
- check out the AP report

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.